Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety study of darunavir with low-dose ritonavir in highly treatment-experienced HIV-1 infected patients
2005-000793-45Phase 3Completed
- Sponsor
- Tibotec
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of darunavir in Human immunodeficiency virus infection type 1, sponsored by Tibotec. Primary endpoint: Intent-to-treat safety assessment. Started May 2006; status: completed.
02
Drugs
darunavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-000793-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000793-45.